Board of Directors

Board of Directors

Jeffrey Wolf

Jeffrey Wolf is founder and CEO of Heat Biologics, and co-founder of Pelican Therapeutics. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon breakthrough research.

Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground-up, and has played an active role in supporting the growth of his companies. Mr. Wolf’s start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic; EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases; and GenerationOne (founder and CEO), one of the first mobile-based health companies focused on disease management.

Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in economics.

John Prendergast, Ph.D.
Lead Independent Director

John Prendergast is co-founder of Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. He has been chairman of the board at Palatin since June 2000 and director since August 1996. Dr. Prendergast is also president of Summercloud Bay, an independent consulting firm providing services to the biotechnology industry, and director and executive board chairman of Antyra, a privately-held biopharmaceutical firm.

From 1991 through 1997, he was managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, and a C.S.S. in administration and management from Harvard University.

John Monahan, Ph.D.

Dr. Monahan is currently the Chief Technology Officer of Synthetic Biologics, Inc., a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses.

Dr. Monahan co-founded Avigen (NASDAQ:AVGN), which has become a leader in the development of novel pharmaceutical products for the treatment of serious human diseases. As CEO for 12 years, he raised more than $235M in private and public financings, including its IPO.

Prior to Avigen, Dr. Monahan was VP of R&D at Somatix Therapy Corp.; served as director of molecular and cell biology at Triton Biosciences; held the role of research group chief of molecular genetics at Hoffmann-LaRoche; and was an instructor at Baylor College of Medicine in Houston.

Dr. Monahan received his Ph.D. in biochemistry from McMaster University, and B.Sc. from University College Dublin. He is a board member of Itus, Corp. and Tacere Therapeutics, as well as a number of Irish biotech companies, including Genable, Cellix, Luxcel, Identigen, Pharmatrin and GK Technologies.

Edward B. Smith, III

Edward Smith is managing partner of Aristar Capital Management, LLC, and also serves as director at Z Trim Holdings, Inc., an agricultural biotechnology company focused on transforming biomass for uses within food and industrial markets. Previously, he was managing partner of Brightline Capital Management, LLC. Prior to founding BCM, Mr. Smith worked at Gracie Capital, GTCR Golder Rauner and Credit Suisse.

Previous roles include positions at Gracie Capital, GTCR Golder Rauner and Credit Suisse First Boston. Mr. Smith holds a B.A. in social studies from Harvard University and an M.B.A. from Harvard Business School.